Publications by authors named "M E Heath-Chiozzi"
Article Synopsis
- Chronic inducible urticaria (CIndU), a condition caused by mast cell-mediated allergic reactions, can be effectively treated with barzolvolimab, a humanized antibody that inhibits mast cell activation by stem cell factor (SCF).* -
- In a trial involving patients unresponsive to antihistamines, one dose of barzolvolimab resulted in significant mast cell depletion and reduced levels of tryptase, leading to improved urticaria control and quality of life.* -
- The treatment was well tolerated with mostly mild side effects, and 95% of patients showed complete responses within 12 weeks, indicating strong potential for barzolvolimab in treating mast cell-related disorders.*
In phase I development, CDX-3379, an anti-ErbB3 monoclonal antibody, showed promising molecular and antitumor activity in head and neck squamous cell carcinoma (HNSCC), alone or in combination with cetuximab. Preliminary biomarker data raised the hypothesis of enhanced response in tumors harboring mutations. This phase II, multicenter trial used a Simon 2-stage design to investigate the efficacy of CDX-3379 and cetuximab in 30 patients with recurrent/metastatic, HPV-negative, cetuximab-resistant HNSCC.
View Article and Find Full Text PDFBackground: Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory, and pruritic disorders when activated. MC-targeted therapies are approved in several disorders, yet many patients have limited benefit suggesting the need for approaches that more broadly inhibit MC activity. MCs require the KIT receptor and its ligand stem cell factor (SCF) for differentiation, maturation, and survival.
View Article and Find Full Text PDFUnlabelled: Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity. In this study, we sought to better understand the potential off-target toxicities of new DAAs. We retrospectively evaluated the clinical and pathological findings of the sentinel case in a phase II study that led to clinical development discontinuation for BMS-986094, an HCV nucleotide polymerase (nonstructural 5B) inhibitor.
View Article and Find Full Text PDFObjectives: Describe the population characteristics of liver chemistries, the incidence and patterns of liver chemistry abnormalities, and the longitudinal behavior of alanine aminotransferase in mild-to-moderate asthmatic patients.
Methods: We undertook a retrospective analysis of comparator arm data from a long-term safety surveillance study of a leukotriene inhibitor.
Results: Several liver chemistry elevations relative to the upper limit of normal were observed.